



Faculty Work Comprehensive List

3-19-2019

Association of Reported Fish Intake and Supplementation Status with the Omega-3 Index

Kristina H. Jackson

Jason M. Polreis

Nathan L. Tintle

Dordt College, nathan.tintle@dordt.edu

Penny M. Kris-Etherton

Pennsylvania State University

William S. Harris

University of South Dakota

Follow this and additional works at: https://digitalcollections.dordt.edu/faculty_work



Part of the [Dietetics and Clinical Nutrition Commons](#)

Recommended Citation

Jackson, K. H., Polreis, J. M., Tintle, N. L., Kris-Etherton, P. M., & Harris, W. S. (2019). Association of Reported Fish Intake and Supplementation Status with the Omega-3 Index. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 142, 4. <https://doi.org/10.1016/j.plefa.2019.01.002>

This Article is brought to you for free and open access by Digital Collections @ Dordt. It has been accepted for inclusion in Faculty Work Comprehensive List by an authorized administrator of Digital Collections @ Dordt. For more information, please contact ingrid.mulder@dordt.edu.

Association of Reported Fish Intake and Supplementation Status with the Omega-3 Index

Abstract

Background: An Omega-3 Index (O3I; EPA+DHA as a % of erythrocyte total fatty acids) in the desirable range (8%-12%) has been associated with improved heart and brain health.

Objective: To determine the combination of fish intake and supplement use that is associated with an O3I of >8%.

Design: Two cross-sectional studies comparing the O3I to EPA+DHA/fish intake.

Participants/setting: The first study included 28 individuals and assessed their fish and EPA+DHA intake using both a validated triple-pass 24-hr recall dietary survey and a single fish-intake question. The second study used de-identified data from 3,458 adults (84% from US) who self-tested their O3I and answered questions about their fish intake and supplement use.

Statistical analyses performed: Study 1, chi-squared, one-way ANOVA, and Pearson correlations were computed. In Study 2, multi-variable regression models were used to predict O3I levels from reported fish/supplement intakes.

Results: The mean \pm SD O3I was $4.87 \pm 1.32\%$, and $5.99 \pm 2.29\%$ in the first and second studies, respectively. Both studies showed that for every increase in fish intake category the O3I increased by 0.50–0.65% ($p < 0.0001$). In the second study, about half of the population was taking omega-3 supplements, 32% reported no fish intake and 17% reported eating fish >2 times per week. Taking an EPA+DHA supplement increased the O3I by 2.2% ($p < 0.0001$). The odds of having an O3I of $\geq 8\%$ were 44% in the highest intake group (≥ 3 servings/week and supplementation) and 2% in the lowest intake group (no fish intake or supplementation); and in those consuming 2 fish meals per week but not taking supplements (as per recommendations), 10%.

Conclusion: Current AHA recommendations are unlikely to produce a desirable O3I. Consuming at least 3 fish servings per week plus taking an EPA+DHA supplement markedly increases the likelihood of achieving this target level.

Keywords

omega-3 fatty acids, omega-3 index, eicosapentaenoic acid, docosahexaenoic acid, food frequency questionnaire, dietary records, fish, dietary supplements

Disciplines

Dietetics and Clinical Nutrition

Comments

Online article information:

<https://www.sciencedirect.com/science/article/abs/pii/S0952327818302254#!>

1 **TITLE: Association of Reported Fish Intake and Supplementation Status with the Omega-**
2 **3 Index**

3 **AUTHORS:** K. H. Jackson^a, J. M. Polreis^a, N. L. Tintle^b, P. M. Kris-Etherton^c, W. S. Harris^{a,d}

4 **AFFILIATIONS:** ^aOmegaQuant, LLC, Sioux Falls, SD; ^bDepartment of Mathematics and
5 Statistics, Dordt College, Sioux Center, IA; ^cDepartment of Nutritional Sciences, The
6 Pennsylvania State University, University Park, PA; ^dSanford School of Medicine – University
7 of South Dakota, Sioux Falls, SD

8 Corresponding Author:

9 Kristina H. Jackson, PhD, RD

10 OmegaQuant, LLC. 5009 W. 12th st, Suite 8, Sioux Falls, SD 57106

11 605-271-6917

12 kristina@omegaquant.com

13

14 **Source of support.** This research did not receive any specific grant from funding agencies in the
15 public, commercial, or not-for-profit sectors.

16 **Disclosures.** KHJ and JMP are employees, and WSH is the President of OmegaQuant, LLC, a
17 commercial laboratory that offers the Omega-3 Index test. NLT and PMKE have nothing to
18 disclose.

19

ABSTRACT

20
21 *Background.* An Omega-3 Index (O3I; EPA+DHA as a % of erythrocyte total fatty acids) in the
22 desirable range (8%-12%) has been associated with improved heart and brain health.

23 *Objective.* To determine the combination of fish intake and supplement use that is associated
24 with an O3I of >8%.

25 *Design.* Two cross-sectional studies comparing the O3I to EPA+DHA/fish intake.

26 *Participants/setting.* The first study included 28 individuals and assessed their fish and
27 EPA+DHA intake using both a validated triple-pass 24-hr recall dietary survey and a single fish-
28 intake question. The second study used de-identified data from 3,458 adults (84% from US) who
29 self-tested their O3I and answered questions about their fish intake and supplement use.

30 *Statistical analyses performed.* Study 1, chi-squared, one-way ANOVA, and Pearson correlations
31 were computed. In Study 2, multi-variable regression models were used to predict O3I levels
32 from reported fish/supplement intakes.

33 *Results.* The mean \pm SD O3I was $4.87 \pm 1.32\%$, and $5.99 \pm 2.29\%$ in the first and second studies,
34 respectively. Both studies showed that for every increase in fish intake category the O3I
35 increased by 0.50-0.65% ($P < 0.0001$). In the second study, about half of the population was
36 taking omega-3 supplements, 32% reported no fish intake and 17% reported eating fish >2 times
37 per week. Taking an EPA+DHA supplement increased the O3I by 2.2% ($P < 0.0001$). The odds of
38 having an O3I of $\geq 8\%$ were 44% in the highest intake group (≥ 3 servings/week and
39 supplementation) and 2% in the lowest intake group (no fish intake or supplementation); and in
40 those consuming 2 fish meals per week but not taking supplements (as per recommendations),
41 10%.

42 *Conclusions.* Current AHA recommendations are unlikely to produce a desirable O3I.
43 Consuming at least 3 fish servings per week plus taking an EPA+DHA supplement markedly
44 increases the likelihood of achieving this target level.

45 **Keywords:** omega-3 fatty acids, omega-3 index, eicosapentaenoic acid, docosahexaenoic acid,
46 food frequency questionnaire, dietary records, fish, dietary supplements

47 **Abbreviations:** American Heart Association, AHA; eicosapentaenoic acid, EPA
48 docosahexaenoic acid, DHA; fatty acid, FA; Omega-3 Index, O3I (EPA+DHA as a percent of
49 total erythrocyte FAs).

50 **Author contributions.** All authors participated in (1) the conception and design of the study, or
51 acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it
52 critically for important intellectual content, and (3) final approval of the version to be submitted.

53

1. INTRODUCTION

54 In 2018, the American Heart Association (AHA) updated its 2002 recommendations
55 regarding fish and seafood consumption from "...a variety of (preferably oily) fish at least twice
56 a week" [1] to "...1 to 2 seafood meals per week" [2]. This apparent downgrade in the
57 recommendation (i.e., removal of "preferably oily" and "at least") was made despite evidence
58 that consuming fish more frequently (such as daily or multiple times per day) may impart even
59 greater cardioprotection [3-5]. An online commentary by Kuller that accompanied the
60 publication of the new AHA guidelines questioned whether the new fish intake recommendations
61 would produce cardioprotective blood omega-3 levels [6]. He argued that intake
62 recommendations should be based on those that achieve a target blood level.

63 Asking individuals about their fish intake is often a proxy measure for intake of omega-3
64 fatty acids (FAs) eicosapentaenoic (EPA) and docosahexaenoic acids (DHA), because, in nature,
65 EPA and DHA are found almost exclusively in oily fish, such as salmon, herring and mackerel.
66 Blood levels of EPA and DHA have been shown to be related to reported fish intake [7] and
67 supplementation [8], and to cardiovascular health [9], a single biomarker representing both
68 dietary intake and risk for disease.

69 The Omega-3 Index (O3I) is a measure of the proportion of EPA and DHA in
70 erythrocytes (EPA+DHA/total FAs) and was originally proposed as a risk factor for cardiac
71 death in 2004 by Harris and Von Schacky [10]. Recently, a pooling study of 10 cohort studies
72 confirmed that an O3I of 8% was related to a risk reduction of 35% for cardiovascular death, as
73 compared to 4% (typical O3I in low-fish intake individuals) [9]. While the O3I is a significant
74 predictor of fatal cardiovascular events, research has shown that higher blood omega-3 levels are

75 beneficially related to other aging-related health conditions also, such as cognitive function [11]
76 and brain volume [12] and increased longevity [13, 14].

77 There is some controversy regarding the effects of fish intake on the O3I. For example,
78 Block et al reported that individuals reporting an intake of at least 2 fish meals per week had an
79 O3I of 5.1% [7], and Harris et al. found that after 4 months of consuming 2 oily fish meals per
80 week, the mean O3I was 6.1% [15]. On the other hand, Sands et al. reported a mean O3I of 8%
81 in non-supplementing subjects reporting this weekly intake [16]. So, whether a diet including
82 only 2 servings of fish per week would result in a cardioprotective O3I (8%) or not is unclear.
83 To address this question, we conducted two studies. The first was a small but intensive study
84 using standard dietary intake tools to quantify both fish and EPA+DHA intake and then to
85 correlate these with the O3I. The second was conducted in a “real-world” setting to determine
86 the associations between self-reported intake of fish and/or omega-3 (i.e., EPA and DHA)
87 supplements and the O3I.

88

89

2. SUBJECTS AND METHODS

90 2.1 Study 1

91 The study utilized a cross-sectional design with one clinic visit and three, 24-hour dietary
92 recalls collected within two weeks of the visit. A sample of generally healthy adults was
93 recruited by email and fliers in two sites, State College, PA and Sioux Falls, SD, US, and
94 screened via telephone or in person during the summer of 2009. Eligibility criteria included
95 generally healthy men and women, aged 19-65 years, BMI 19-40 kg/m², not taking any fish oil
96 or other EPA or DHA-containing supplements within the last 2 months, not taking flaxseed oil
97 supplements within the last week, and having a stable diet pattern, especially with respect to
98 seafood, for the previous 6 months. Those who were ineligible were pregnant or nursing, ill,
99 taking prescription medications, smokers, or did not fit into an available fish intake group (see
100 below). Thirty participants were recruited; 28 were eligible and had reasonable responses on the
101 questionnaires. The study visit consisted of a finger prick to collect a dried blood spot, a short
102 questionnaire, and measuring height and weight. The Institutional Review Boards at both sites
103 (Penn State and Sanford Research, Sioux Falls, SD) approved all study procedures.

104 2.1.1 Dietary Assessment

105 The dietary assessment consisted of triplicate 24-hour dietary recalls, and a single
106 screening question derived from the Cardiovascular Health Study [17]. Three dietary recalls were
107 collected via telephone by trained interviewers at The Pennsylvania State University Diet
108 Assessment Center within 2 weeks of the clinic visit. Dietary intake data were analyzed by using
109 the Nutrition Data System for Research software, version 2009, developed by the Nutritional
110 Coordinating Center at the University of Minnesota, Minneapolis, Minnesota. Diet recalls were
111 conducted on unannounced, random, non-consecutive days with at least one weekend day of data

112 by using a multi-pass methodology [18, 19]. At the clinic visit, a single screening question was
113 used to estimate the person's perceived, average intake of "fatty" fish [7]. The screening question
114 was, "How often do you eat—as a main course—tuna or other non-fried fish?" Possible
115 responses were a) 1 or fewer times per month, b) 2-3 times per month, c) 1 time per week, d) 2
116 times per week, or e) more than 2 times per week. A serving was defined as 3 ounces to the
117 participants. Recruitment continued until six participants in each of the five fish intake
118 categories above had been enrolled.

119 2.2 Study 2

120 Data were derived from 3,458 individuals who 1) sent in a dried blood spot to
121 OmegaQuant, LLC (Sioux Falls, SD, US) for testing between March 30, 2017 – January 15,
122 2018, 2) answered questions regarding their fish and omega-3 supplement intake (see below),
123 and 3) were at least 18 years of age. Individuals purchased O3I tests directly online, or they were
124 tested at conferences or expositions, by their health care provider, or in workplace screenings.
125 Identifying information (names, physical addresses [except state and country], email addresses,
126 phone numbers) were removed from the dataset. The dataset contained samples from 28
127 countries. Approval to use de-identified, existing data was obtained from the University of South
128 Dakota Institutional Review Board.

129 2.2.1 Dietary and Demographic Information

130 Individuals completed a short form included in their blood sample collection kit. This
131 form included personal contact information for returning results as well as some demographic
132 (age, sex, country) and dietary intake information. The fish-related dietary question was the same
133 as asked in Study 1, however the possible responses were slightly different: "None per week,"
134 "Every other week," "Every week," "2 times per week," and "3 or more times per week." The

135 supplement-related questions were as follows: “Do you take an omega-3 supplement?” with the
136 responses: “Yes” or “No.” If yes, they were asked which kind of supplement: “Fish oil,” “Krill
137 oil,” “Algal oil,” and “Flaxseed oil.” The supplements with EPA+DHA (krill, fish, and algal oils;
138 n=1,681) were included in the “EPA+DHA supplement” category, but individuals who reported
139 taking flaxseed oil (n=45) or did not report the kind of supplement (n=75) were excluded from
140 this analysis.

141 *2.3 Omega-3 Index Analysis*

142 In both studies, an O3I kit was used to collect a dried blood spot as previously described
143 [20]. After receipt in the laboratory, capillary column gas chromatography was used with an
144 internal-standard-based, three-point calibration curve to quantify levels of 24 FAs. Blood spots
145 were transferred to a reaction vial. FA methyl esters were generated using boron trifluoride in
146 methanol as a methylation reagent. Samples were heated for 45 min at 100C, extracted into
147 hexane (after the addition of water) and analyzed using a GC2010 Gas Chromatograph
148 (Shimadzu Corporation, Columbia, MD) equipped with a SP2560, 100-m column (Supelco,
149 Bellefonte, PA). FA were identified by comparison with a standard mixture of FA (GLC,
150 Nucheck Prep, Elysian, MN). The O3I (an erythrocyte-specific metric) was calculated from the
151 dried blood spot EPA+DHA value using an equation derived by comparing values in 98 random
152 samples and is expressed as a percent of total FAs. The correlation coefficient between O3I and
153 the dried blood spot EPA+DHA was 0.96 (P<0.0001). The laboratory coefficient of variation for
154 the O3I is <5%. All individual FA, including EPA and DHA, are whole blood levels.

155 *2.4 Statistical Analyses*

156 In study 1, demographic characteristics were compared across fish intake groups using
157 chi-squared and one-way ANOVA methods, with p-values also estimated using a resampling

158 approach to ensure robustness due to small sample sizes within each category. Pearson
159 correlations were computed between the O3I and both the frequency of intake (1 question) and
160 the calculated EPA+DHA intake from the dietary recalls, with multiple regression models used
161 to estimate correlations after adjusting for demographic factors (BMI, age, sex, race). In study 2,
162 multiple regression models were used to estimate the adjusted effects of intake frequency and
163 supplementation on blood FA levels, after adjusting for demographic covariates. Seventy-five
164 percent prediction intervals are calculated in order to provide estimates of the range of O3I
165 values based on reported fish consumption, supplement and age, based on a multiple regression
166 model. A significance level of 0.05 and two-sided tests were used for all analyses which were
167 run using R version 3.5 (www.r-project.org).

168

3. RESULTS

169 *3.1 Study 1 (n=28)*

170 Demographic characteristics were not significantly different among the five fish intake
171 groups (Table 1). Overall, the mean age was 32 years and BMI, 24.3 kg/m². All participants
172 were from the US, 82% were Caucasian, and 75% were female (Table 1). Based on the 24-hour
173 dietary recall data, the most commonly eaten fish was tuna (32% of fish eaten) followed by
174 salmon (16%), both of which are species known for their high EPA+DHA content. Eight other
175 varieties of fish and shellfish (cod, imitation crab, shrimp, haddock, catfish, swordfish, mussel,
176 sardines) were significant contributors of EPA+DHA (based on providing at least 0.05g
177 EPA+DHA in the meal- not energy adjusted). Estimated overall EPA+DHA intakes were 300
178 mg/d (assuming 2000 kcal intake, Table 1), ranging from about 34 to 620 mg/day across fish
179 intake categories.

180 The association between the O3I (and whole blood EPA and DHA separately) and both
181 the five fish intake groups and the calorie-adjusted intake of EPA and DHA were significant. For
182 the former comparison, the Pearson correlation coefficients were 0.48 for EPA ($p=0.009$), 0.59
183 for DHA ($p<0.001$) and 0.61 for the O3I ($p<0.001$). There was an estimated 0.6 percentage point
184 increase in the O3I for each additional fish consumption category (Table 2). In a multivariable
185 model containing all four subject demographic factors and reported fish consumption frequency,
186 only the latter was a significant predictor of the O3I. The associations between the O3I and
187 calculated EPA and DHA intakes were weaker than those comparing the former with fish intake
188 frequency. Correlations between blood FAs and calculated intakes were 0.26 for EPA ($p=0.17$),
189 0.44 for DHA ($p=0.02$), and 0.42 for the O3I ($p=0.03$). Correlations between fish frequency
190 group and calculated EPA+DHA intakes were 0.61 (EPA), 0.59 (DHA) and 0.61 (EPA+DHA).

191 3.2 Study 2 (n=3,458)

192 The mean age of this cohort was 51 years, over half were women (60%), and they were
193 primarily from the US (84%) (Table 3). Approximately half of the sample reported taking an
194 EPA+DHA supplement at the time of the study (includes fish, krill and algal oil supplements).
195 Slightly less than one third of the sample reported never eating fish, with another similarly sized
196 group reporting each fish approximately every other week, and the remaining individuals
197 reporting fish consumption at least weekly (38%). About 83% of individuals had an O3I below
198 the desirable range of 8%-12%, 16% had values within that range, and 2% had values above.

199 Individuals taking EPA+DHA supplements and/or eating fish more frequently had higher
200 O3I values (Figure 1, Table 4). Furthermore, older individuals and individuals from outside of
201 the US tended to have higher O3I values (Table 4). All variables remained statistically
202 significant in a multi-variable model predicting O3I values, with an estimated increase of 2.2%
203 when taking an EPA+DHA supplement, and an estimated 0.6% increase for each additional fish
204 meal per week. The multi-variable model explained 32.7% of the variance in the O3I.

205 Using a multivariable model including only age, reported frequency of fish intake, and
206 omega-3 supplement use, a hypothetical 50-yr old person who did not take supplements and
207 reported no fish intake would be predicted to have an O3I of about 4.5% (75% prediction
208 interval [PI]: 2.3% to 6.7%). At the other extreme, the same individual reporting both
209 supplement use and three or more fish meals per week would have an O3I of 8.6% (75% PI,
210 6.4% to 10.8%) (Table 5).

211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233

4. DISCUSSION

The overall purpose of these studies was to answer the question, “How much EPA+DHA from fish and/or supplements is needed to achieve a desirable O3I?” Using the answers to two simple dietary questions – “How often to you eat tuna or other non-fried fish?” and, “Do you take an omega-3 supplement?” – allowed us (along with age) to begin to answer that question.

Two studies were reported here. The aim of the first study was to determine whether the answer to a simple fish intake question was as good as a calculated EPA+DHA intake from an intensive, triple 24-hr recall intake survey, with regards to their correlations with the O3I. We found stronger correlations with the O3I for the one question than for the more rigorous (but apparently less useful) recall method. The reason for this is likely that for nutrients (like EPA and DHA) that are provided in high amounts by a very small number of foods, a 3-day diet record is very unlikely to capture the “true” average intake. If the fish meal day happens to be included in the 3 days, the overall average intake will be over-estimated; if the fish meal is not eaten in that 3 day window, the average intake will be under-estimated. This increases variability and thus lowers correlations with biomarkers that actually do represent an average intake. The aim of the second study was to determine, in a large cohort of people who self-reported fish and supplement intake, what combination of these two sources of EPA and DHA was required to achieve an O3I of >8%. We found that those with the best chance (44%) of achieving an desirable O3I were reporting the consumption of at least 3 fish meals a week and were taking an EPA+DHA supplement.

It is of interest to know how much EPA+DHA would be provided by >2 fish meals/wk + supplementation. We estimated this using the following assumptions: 1) a serving of oily fish provides about 1,250 mg EPA+DHA (average amount provided by 4 oz of wild coho salmon,

234 Bluefin tuna, sardines and Albacore tuns, from USDA Nutrient Database[21]), and 2) a standard
235 fish oil capsule contains about 300 mg EPA+DHA. Based on these values, amount of
236 EPA+DHA from fish for 3 servings per week would be 3,750 mg/wk (or 535 mg EPA+DHA per
237 day). Add 300 mg EPA+DHA per day from one supplement, and the overall intake equals
238 around 835 mg EPA+DHA per day. This is approximately how much EPA+DHA one would
239 need to consume in the long-term to achieve an average O3I of 8%, but it is >3 times the
240 EPA+DHA recommended by the Dietary Guidelines for Americans (250 mg/day) [22], and 1.7
241 times that recommended by the Academy of Nutrition and Dietetics (500 mg/day) [23]. It is also
242 about 8 times the typical EPA+DHA intake in the US (~100 mg/day) [24]. Only about 10% of
243 Americans eat as much as 2 fish meals per week [DGAC 2015]. Not surprisingly, an estimated
244 95% of Americans do not have optimal O3I levels [25]. In 2007 we reported that 2 fish meals per
245 week (salmon and albacore tuna) provided an average of 485 mg EPA+DHA per day, and after
246 months of this regimen, the mean O3I increased from 4% to 6.2% [15]. This observation further
247 underscores the inability of the AHA recommendations to produce an optimal O3I.

248 Therefore, there is a discrepancy between the amount of EPA+DHA provided by current
249 fish intake recommendations (250-500 mg/d) vs. the amount needed by most Americans to reach
250 an O3I of 8% (>800 mg/d, according to our calculations). As Kuller wrote in a commentary on
251 the 2018 AHA fish intake guidelines, “The key public health question is whether the
252 recommended intake of seafood in the US should be [set so as] to reach the same levels of n-3
253 PUFAs in blood as in Japan, about 9% of total FAs in blood versus 4% in the US [26].” Based on
254 this rationale (and our data), *at least* 2-3 servings per week of *oily* fish, rather than “1-2 servings
255 of seafood” [2], should be the recommendation. But even this will not produce an O3I of >8% -
256 to achieve that, either adding an EPA+DHA supplement or increasing to 4-5 servings of oily fish
257 per week would be necessary.

258 What was the basis for the AHA’s recommendation of “1-2 seafood meals per week?”
259 Rimm et al.[2] stated that “...there is little additional benefit in risk reduction with a higher
260 intake [than 1-2 servings per week].” This, in our view, does not reflect the current state of the
261 data. Considerable evidence supports the view that higher fish intakes and higher blood levels of
262 omega-3s are associated with significant additional reduction in cardiovascular risk [3, 5, 27,
263 28], in a dose-dependent manner with no plateau at 1-2 servings per week. The biggest reduction
264 in risk may well occur between zero servings and 1-2 servings per week, but to suggest that there
265 is no additional benefit at high intakes and blood levels ignores a substantial body of evidence
266 cited above. We do recognize that public health recommendations must balance what is ideal vs.
267 what is practical for the public, and also must take into consideration other non-nutritional
268 factors, i.e. potentially hazardous components of fish (mercury, PCBs) and the sustainability of
269 the world’s fish supply. However, the basis for concluding that there is “no evidence” that higher
270 fish intakes are associated with improved outcomes is obscure at best.

271 Why is an O3I of 8% the desirable level? The O3I was originally presented as a risk
272 factor for cardiac death, which is where the cut-offs for desirable (>8%) and undesirable (<4%)
273 [10] were estimated from the data available prior to 2004. Recently, a meta-analysis from 10
274 prospective cohort studies has confirmed that an 8% O3I was associated with a 35% reduction in
275 risk for fatal CHD compared to an Index of <4% [9, 27]. In another report, a level of 8% or
276 greater (extrapolated from whole blood EPA+DHA levels) was significantly associated with the
277 slowest rate of telomere attrition [13], and in the Women’s Health Initiative Memory Study,
278 those with an Index of 8% or greater had a 31% lower risk of death from any cause over the
279 ensuing 15 years [13]. Similarly, individuals with a O3I of 7.8% (median of the highest quintile
280 in the Framingham Offspring Study) were 34% less likely to die from any cause over 7 years of
281 follow-up compared to those with an Index of 3.7% (median of the lowest quintile) [28]. In

282 addition, an Index at this level was linked with better cognitive performance [11], improved
283 depressive symptoms [29, 30], better cardiac remodeling post myocardial-infarction [31], lower
284 odds of being an acute coronary syndrome patient [32], improved arthritis symptoms [33], and
285 better cognitive function/brain size in B-vitamin-treated subjects [34]. This is also the range
286 typical of the traditional Japanese [35], a population with a very low CHD rate and one of the
287 longest life-expectancies in the world [36]. Finally, as emphasized by Myer and DeGroot, RCTs
288 which achieved an O3I of 8% were more likely to see CVD benefits [37]. Thus, there is
289 substantial evidence supporting a target of 8% or more as optimal.

290 Although an O3I of 8% is a reasonable therapeutic target, is it realistic? Can it be
291 achieved with diet alone? Clearly, it can, again based on the Japanese experience. There, the
292 median fish consumption is ~3 fish servings per week, resulting in an estimated 750 – 1,000 mg
293 EPA+DHA per day [4, 38]. Interestingly, this intake is similar to the ~835 mg/day calculated
294 above for 3 fish meals + supplementation. The average erythrocyte EPA+DHA levels in Japan
295 range from 6.8 – 9.0%, depending on the study and population [4, 38, 39]. So, yes, an O3I >8%
296 is achievable by diet alone. But Japan is fairly unique. In the US the average fish intake is less
297 than 1 serving per week which provides approximately 100 mg EPA+DHA per day [24]). The
298 average O3I for Americans ranges from 4%-6% [25]. So, short of adopting the Japanese diet (for
299 a lifetime), it appears that taking an EPA+DHA supplement could be an important for achieving
300 a cardioprotective O3I. The O3I calculator (<https://omegaquant.com/omega-3-calculator/>) is a
301 useful tool to roughly estimate how much more EPA+DHA one needs to eat in order to achieve a
302 desirable O3I level based on their current levels and intake [8]. For example, according to the
303 calculator, a man with an O3I of 4.5% would need an estimated 951 mg EPA+DHA per day to
304 reach 8%. To get ~950 mg EPA+DHA per day, he could start by eating three wild sockeye
305 salmon meals per week (at 974 mg EPA+DHA per 4-oz. serving), which would amount to 417

306 mg EPA+DHA per day [21]. Then he could add at least 500 mg EPA+DHA per day through
307 taking a supplement, for a total of 917 mg EPA+DHA per day. Alternatively, he could achieve
308 this intake by eating oily fish almost every day: two servings of sockeye salmon (974 mg
309 EPA+DHA per 4 oz serving), two cans of Albacore tuna (1483 mg EPA+DHA) and two cans of
310 sardines (903 mg EPA+DHA) per week. Or finally, he could eat no fish at all and take 3
311 standard fish oil capsules per day (900 mg EPA+DHA). Whatever the approach, it would need to
312 be consistent for at least 4 months in order to reach a new steady state O3I[40].

313 This study had significant limitations which may have contributed to the wide variability
314 in the O3I across intake/supplementation categories. First, the single fish question was vague
315 with regards to the actual types of fish consumed, and the supplement question did not take doses
316 and frequency of supplementation into account. This is the price one pays for creating simple,
317 consumer-directed questions instead of complex, research-based questions. Second, individual
318 variability in O3I levels could be due to genetic and biological differences (age [25], genetic
319 variants [41]) affecting the incorporation of FAs into tissue. Finally, there is always the chance
320 that the individuals misreported their dietary intake, making the relationship between the
321 reported intake and O3I seem incongruent on an individual basis. Therefore, these two questions,
322 although useful at a population level, are probably less so for the individual. It should be
323 emphasized that this cohort is in no way “representative” of the omega-3 status of each
324 individual country from which these samples were collected. These individuals were typically
325 attending trade shows and thus were much more likely to be interested in omega-3 FAs than the
326 average person, and hence probably consumed more fish/fish oil. Thus, these data are not
327 generalizable to the populations tested, but they were appropriate to address our study question.
328 This was also a cross sectional study in which only one blood sample and only one response to
329 the questions asked were available. Multiple data points per person would likely have reduced

330 the variability. There were also significant strengths with this study, including the large, real-
331 world cohort with self-reported dietary intake, the use of an objective FA biomarker of omega-3
332 status, and the inclusion of a well-validated and widely-used dietary intake tool.

333 **5. CONCLUSION**

334 The current study again validates the O3I as a useful biomarker of EPA+DHA intake.
335 Reports of higher fish intake corresponded with higher O3I values in a dose-dependent manner.
336 Reported supplementation with EPA+DHA (fish, krill, or algal oils) was associated with an
337 approximately 2 percentage point higher O3I. The current fish intake recommendations (1-2
338 servings of seafood per week) are unlikely to produce a cardioprotective O3I level, but
339 consuming primarily oily fish 3 times or more per week and supplementation may. Despite these
340 strong relationships, individual variability is great, and testing blood levels is the only way to
341 confirm the omega-3 status.

342

6. REFERENCES

- 344 [1] P.M. Kris-Etherton, W.S. Harris, L.J. Appel, C. American Heart Association. Nutrition. Fish
345 consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation*. 106 (2002)
346 2747-2757.
- 347 [2] E.B. Rimm, L.J. Appel, S.E. Chiuve, L. Djousse, M.B. Engler, P.M. Kris-Etherton, D.
348 Mozaffarian, D.S. Siscovick, A.H. Lichtenstein, L. American Heart Association Nutrition
349 Committee of the Council on, H. Cardiometabolic, E. Council on, Prevention, Y. Council on
350 Cardiovascular Disease in the, C. Council on, N. Stroke, C. Council on Clinical. Seafood Long-
351 Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From
352 the American Heart Association. *Circulation*. 138 (2018) e35-e47.
- 353 [3] K. He, Y. Song, M.L. Daviglius, K. Liu, L. Van Horn, A.R. Dyer, P. Greenland. Accumulated
354 evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort
355 studies. *Circulation*. 109 (2004) 2705-2711.
- 356 [4] H. Iso, M. Kobayashi, J. Ishihara, S. Sasaki, K. Okada, Y. Kita, Y. Kokubo, S. Tsugane.
357 Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan
358 Public Health Center-Based (JPHC) Study Cohort I. *Circulation*. 113 (2006) 195-202.
- 359 [5] K. Hamazaki, H. Iso, E.S. Eshak, S. Ikehara, A. Ikeda, M. Iwasaki, T. Hamazaki, S. Tsugane,
360 J.S. Group. Plasma levels of n-3 fatty acids and risk of coronary heart disease among Japanese:
361 The Japan Public Health Center-based (JPHC) study. *Atherosclerosis*. 272 (2018) 226-232.
- 362 [6] L.H. Kuller. Omega-3 fatty acids and coronary heart disease: A very fishy story. 2018.
363 [https://professional.heart.org/professional/ScienceNews/UCM_501197_Omega-3-Fatty-Acids-](https://professional.heart.org/professional/ScienceNews/UCM_501197_Omega-3-Fatty-Acids-and-Coronary-Heart-Disease-A-Very-Fishy-Story.jsp)
364 [and-Coronary-Heart-Disease-A-Very-Fishy-Story.jsp](https://professional.heart.org/professional/ScienceNews/UCM_501197_Omega-3-Fatty-Acids-and-Coronary-Heart-Disease-A-Very-Fishy-Story.jsp). 7/26/2018:
- 365 [7] R.C. Block, W.S. Harris, J.V. Pottala. Determinants of Blood Cell Omega-3 Fatty Acid
366 Content. *Open Biomarkers J*. 1 (2008) 1-6.
- 367 [8] M.R. Flock, A.C. Skulas-Ray, W.S. Harris, T.D. Etherton, J.A. Fleming, P.M. Kris-Etherton.
368 Determinants of Erythrocyte Omega-3 Fatty Acid Content in Response to Fish Oil
369 Supplementation: A Dose-Response Randomized Controlled Trial. *Journal of the American*
370 *Heart Association*. 2 (2013) e000513.
- 371 [9] W.S. Harris, L. Del Gobbo, N.L. Tintle. The Omega-3 Index and relative risk for coronary
372 heart disease mortality: Estimation from 10 cohort studies. *Atherosclerosis*. 262 (2017) 51-54.
- 373 [10] W.S. Harris, C. von Schacky. The Omega-3 Index: a new risk factor for death from
374 coronary heart disease? *Prev.Med*. 39 (2004) 212-220.
- 375 [11] K. Lukaschek, C. von Schacky, J. Kruse, K.H. Ladwig. Cognitive Impairment Is Associated
376 with a Low Omega-3 Index in the Elderly: Results from the KORA-Age Study. *Dementia and*
377 *geriatric cognitive disorders*. 42 (2016) 236-245.
- 378 [12] J.V. Pottala, K. Yaffe, J.G. Robinson, M.A. Espeland, R. Wallace, W.S. Harris. Higher RBC
379 EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI Study.
380 *Neurology*. 82 (2014) 435-442.
- 381 [13] W.S. Harris, J. Luo, J.V. Pottala, M.A. Espeland, K.L. Margolis, J.E. Manson, L. Wang,
382 T.M. Brasky, J.G. Robinson. Red blood cell polyunsaturated fatty acids and mortality in the
383 Women's Health Initiative Memory Study. *J Clin Lipidol*. 11 (2017) 250-259.
- 384 [14] R. Farzaneh-Far, J. Lin, E.S. Epel, W.S. Harris, E.H. Blackburn, M.A. Whooley.
385 Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary
386 heart disease. *JAMA*. 303 (2010) 250-257.

387 [15] W.S. Harris, J.V. Pottala, S.A. Sands, P.G. Jones. Comparison of the effects of fish and fish-
388 oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids. *Am J Clin*
389 *Nutr.* 86 (2007) 1621-1625.

390 [16] S.A. Sands, K.J. Reid, S.L. Windsor, W.S. Harris. The impact of age, body mass index, and
391 fish intake on the EPA and DHA content of human erythrocytes. *Lipids.* 40 (2005) 343-347.

392 [17] D. Mozaffarian, R.N. Lemaitre, L.H. Kuller, G.L. Burke, R.P. Tracy, D.S. Siscovick, S.
393 Cardiovascular Health. Cardiac benefits of fish consumption may depend on the type of fish
394 meal consumed: the Cardiovascular Health Study. *Circulation.* 107 (2003) 1372-1377.

395 [18] J.M. Conway, L.A. Ingwersen, A.J. Moshfegh. Accuracy of dietary recall using the USDA
396 five-step multiple-pass method in men: an observational validation study. *J Am Diet Assoc.* 104
397 (2004) 595-603.

398 [19] J.M. Conway, L.A. Ingwersen, B.T. Vinyard, A.J. Moshfegh. Effectiveness of the US
399 Department of Agriculture 5-step multiple-pass method in assessing food intake in obese and
400 nonobese women. *Am J Clin Nutr.* 77 (2003) 1171-1178.

401 [20] W.S. Harris, J. Polreis. Measurement of the Omega-3 Index in Dried Blood Spots. *Annals of*
402 *Clinical and Laboratory Research.* 4 (2016) e1-e7.

403 [21] US Department of Agriculture, Agricultural Research Service, N.D. Laboratory, USDA
404 National Nutrient Database for Standard Reference, Legacy, in, Internet, 2018 April.

405 [22] U.S.D.o.A.a.U.S.D.o.H.a.H. Services. Dietary Guidelines for Americans, 2010. 2010.
406 <http://www.cnpp.usda.gov/Publications/DietaryGuidelines/2010/PolicyDoc/PolicyDoc.pdf>.

407 [23] P.M. Kris-Etherton, S. Innis. Position of the American Dietetic Association and Dietitians of
408 Canada: Dietary Fatty Acids. *Journal of the American Dietetic Association.* 107 (2007) 1599-
409 1611.

410 [24] Y. Papanikolaou, J. Brooks, C. Reider, V.L. Fulgoni, 3rd. U.S. adults are not meeting
411 recommended levels for fish and omega-3 fatty acid intake: results of an analysis using
412 observational data from NHANES 2003-2008. *Nutrition journal.* 13 (2014) 31.

413 [25] W.S. Harris, J.V. Pottala, S.A. Varvel, J.J. Borowski, J.N. Ward, J.P. McConnell.
414 Erythrocyte omega-3 fatty acids increase and linoleic acid decreases with age: observations from
415 160,000 patients. *Prostaglandins, leukotrienes, and essential fatty acids.* 88 (2013) 257-263.

416 [26] L.H. Kuller. Omega-3 Fatty Acids and Coronary Heart Disease: A Very Fishy Story.
417 *Circulation.* (2018).

418 [27] L.C. Del Gobbo, F. Imamura, S. Aslibekyan, M. Marklund, J.K. Virtanen, M. Wennberg,
419 M.Y. Yakoob, S.E. Chiuve, L. Dela Cruz, A.C. Frazier-Wood, A.M. Fretts, E. Guallar, C.
420 Matsumoto, K. Prem, T. Tanaka, J.H. Wu, X. Zhou, C. Helmer, E. Ingelsson, J.M. Yuan, P.
421 Barberger-Gateau, H. Campos, P.H. Chaves, L. Djousse, G.G. Giles, J. Gomez-Aracena, A.M.
422 Hodge, F.B. Hu, J.H. Jansson, I. Johansson, K.T. Khaw, W.P. Koh, R.N. Lemaitre, L. Lind, R.N.
423 Luben, E.B. Rimm, U. Riserus, C. Samieri, P.W. Franks, D.S. Siscovick, M. Stampfer, L.M.
424 Steffen, B.T. Steffen, M.Y. Tsai, R.M. van Dam, S. Voutilainen, W.C. Willett, M. Woodward,
425 D. Mozaffarian, H. Cohorts for, A. Aging Research in Genomic Epidemiology Fatty, C.
426 Outcomes Research. Omega-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart
427 Disease: Pooling Project of 19 Cohort Studies. *JAMA Intern Med.* 176 (2016) 1155-1166.

428 [28] W.S. Harris, N.L. Tintle, M.R. Etherton, R.S. Vasan. Erythrocyte long-chain omega-3 fatty
429 acid levels are inversely associated with mortality and with incident cardiovascular disease: The
430 Framingham Heart Study. *J Clin Lipidol.* (2018).

431 [29] R.M. Carney, B.C. Steinmeyer, K.E. Freedland, E.H. Rubin, M.W. Rich, W.S. Harris.
432 Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a

433 placebo-controlled trial of omega-3 supplements. *The Journal of clinical psychiatry*. 77 (2016)
434 e138-143.

435 [30] C. Horikawa, R. Otsuka, Y. Kato, Y. Nishita, C. Tange, S. Kakutani, T. Rogi, H.
436 Kawashima, H. Shibata, F. Ando, H. Shimokata. Cross-sectional association between serum
437 concentrations of n-3 long-chain PUFA and depressive symptoms: results in Japanese
438 community dwellers. *The British journal of nutrition*. 115 (2016) 672-680.

439 [31] B. Heydari, S. Abdullah, J.V. Pottala, R. Shah, S. Abbasi, D. Mandry, S.A. Francis, H.
440 Lumish, B.B. Ghoshhajra, U. Hoffmann, E. Appelbaum, J.H. Feng, R. Blankstein, M. Steigner,
441 J.P. McConnell, W. Harris, E.M. Antman, M. Jerosch-Herold, R.Y. Kwong. Effect of Omega-3
442 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The
443 OMEGA-REMODEL Randomized Clinical Trial. *Circulation*. 134 (2016) 378-391.

444 [32] R.C. Block, W.S. Harris, K.J. Reid, S.A. Sands, J.A. Spertus. EPA and DHA in blood cell
445 membranes from acute coronary syndrome patients and controls. *Atherosclerosis*. 197 (2008)
446 821-828.

447 [33] C. Dawczynski, M. Dittrich, T. Neumann, K. Goetze, A. Welzel, P. Oelzner, S. Volker,
448 A.M. Schaible, F. Troisi, L. Thomas, S. Pace, A. Koeberle, O. Werz, P. Schlattmann, S.
449 Lorkowski, G. Jahreis. Docosahexaenoic acid in the treatment of rheumatoid arthritis: A double-
450 blind, placebo-controlled, randomized cross-over study with microalgae vs. sunflower oil. *Clin*
451 *Nutr*. 37 (2018) 494-504.

452 [34] A. Oulhaj, F. Jerneren, H. Refsum, A.D. Smith, C.A. de Jager. Omega-3 Fatty Acid Status
453 Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment.
454 *Journal of Alzheimer's disease : JAD*. 50 (2016) 547-557.

455 [35] M. Itomura, S. Fujioka, K. Hamazaki, K. Kobayashi, T. Nagasawa, S. Sawazaki, Y.
456 Kiriara, T. Hamazaki. Factors influencing EPA+DHA levels in red blood cells in Japan. *In*
457 *Vivo*. 22 (2008) 131-135.

458 [36] *The World Fact Book*, Central Intelligence Agency, Washington, D.C., 2018.

459 [37] B.J. Meyer, R.H.M. Groot. Effects of Omega-3 Long Chain Polyunsaturated Fatty Acid
460 Supplementation on Cardiovascular Mortality: The Importance of the Dose of DHA. *Nutrients*. 9
461 (2017).

462 [38] B.F. Zhou, J. Stamler, B. Dennis, A. Moag-Stahlberg, N. Okuda, C. Robertson, L. Zhao, Q.
463 Chan, P. Elliott, I.R. Group. Nutrient intakes of middle-aged men and women in China, Japan,
464 United Kingdom, and United States in the late 1990s: the INTERMAP study. *J Hum Hypertens*.
465 17 (2003) 623-630.

466 [39] T. Kawabata, S. Hirota, T. Hirayama, N. Adachi, C. Hagiwara, N. Iwama, K. Kamachi, E.
467 Araki, H. Kawashima, Y. Kiso. Age-related changes of dietary intake and blood
468 eicosapentaenoic acid, docosahexaenoic acid, and arachidonic acid levels in Japanese men and
469 women. *Prostaglandins Leukot Essent Fatty Acids*. 84 (2011) 131-137.

470 [40] M.B. Katan, J.P. Deslypere, A.P. van Birgelen, M. Penders, M. Zegwaard. Kinetics of the
471 incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and
472 adipose tissue: an 18-month controlled study. *Journal of lipid research*. 38 (1997) 2012-2022.

473 [41] A. Kalsbeek, J. Veenstra, J. Westra, C. Disselkoen, K. Koch, K.A. McKenzie, J. O'Bott, J.
474 Vander Woude, K. Fischer, G.C. Shearer, W.S. Harris, N.L. Tintle. A genome-wide association
475 study of red-blood cell fatty acids and ratios incorporating dietary covariates: Framingham Heart
476 Study Offspring Cohort. *PloS one*. 13 (2018) e0194882.

477

478

479

480

481 **Table 1. Study 1 demographic, (mean [SD], n[%])**

Characteristic	Overall (n=28)	<1 time per month (n=6)	2-3 times per month (n=6)	1 time per week (n=5) ¹	2 times per week (n=5)	More than 2 times per week (n=6)
<i>Demographics</i>						
Sex – Male	25% (7)	16.7% (1)	16.7% (1)	20% (1)	0% (0)	66.7% (4)
Age (years)	31.6 (9.5)	30.3 (12.0)	34.2 (10.3)	30.2 (6.8)	27.0 (7.5)	35.3 (10.2)
Race - Caucasian	82.1% (23)	83.3% (5)	83.3% (5)	60% (3)	100% (5)	83.3% (5)
BMI (kg/m ²)	24.3 (4.5)	21.9 (3.4)	25.9 (4.8)	27.0 (4.9)	24.2 (6.0)	22.9 (2.7)
<i>Whole blood fatty acid levels (% composition)</i>						
EPA	0.57 (0.43)	0.34 (0.06)	0.43 (0.17)	0.55 (0.28)	0.60 (0.27)	0.93 (0.78)
DHA	3.40 (0.95)	2.57 (0.79)	2.79 (0.52)	3.63 (0.55)	4.10 (0.21)	4.05 (1.16)
Omega-3 Index ¹	4.87 (1.34)	3.77 (0.83)	4.08 (0.52)	5.10 (0.87)	5.65 (0.45)	5.94 (1.94)
<i>Calorie-Adjusted Dietary Intake (g per 1000 kcal)</i>						
EPA	0.05 (0.07)	0.004 (0.002)	0.02 (0.03)	0.06 (0.04)	0.05 (0.04)	0.12 (0.12)
DHA	0.10 (0.12)	0.014 (0.008)	0.06 (0.11)	0.09 (0.09)	0.15 (0.13)	0.19 (0.16)
EPA+DHA	0.15 (0.18)	0.017 (0.01)	0.08 (0.14)	0.15 (0.13)	0.21 (0.16)	0.31 (0.26)

482

483 ¹The O3I is EPA+DHA in erythrocytes which is calculated from the EPA+DHA content of a

484 dried whole blood sample. Hence, the O3I may not equal the EPA+DHA in whole blood.

485

486 **Table 2. Association of fish intake and other characteristics with O3I levels in Study 1.**

Characteristic	Absolute percentage point difference in the O3I per unit of change of the characteristic ¹	
	Bivariate Beta (95% CI)	Multivariable ² Beta (95% CI)
Fish consumption category (meals/week)	0.65% (0.31, 1.00) [†]	0.56% (0.06, 1.07)*
EPA+DHA consumption (per 1000 kcal; log-transformed) ²	0.33% (0.04, 0.63)*	0.17% (-0.24, 0.57)
Sex- Male	0.49% (-0.72, 1.71)	-0.32% (-1.50, 0.87)
Age (per decade)	-0.22% (-0.75, 0.33)	-0.20% (-0.72, 0.29)
Caucasian Race	0.05% (-1.33, 1.45)	-0.18% (-1.42, 1.04)
BMI (kg/m ²)	-0.07% (-0.18, 0.05)	-0.05% (-0.18, 0.07)

487 [†]P<0.0001; *P<0.01

488 ¹Values in this table are beta coefficients and are interpreted as the change in O3I for a one-unit
 489 change in the characteristic, e.g. for each additional fish meal per week the estimated effect on
 490 O3I is 0.65 percentage point increase before and 0.56 percentage point increase after adjusting
 491 for other characteristics. ²Model R² is 0.45. Equation: O3I = 6.62% + 0.56*Estimated fish meals
 492 per week + 0.17*log(EPA+DHA)-0.32*Male-0.20*(Age/10)-0.18*White-0.05*BMI.

493

494

495 **Table 3. Demographics, fish intake, supplementation status and blood fatty acids from**
 496 **study 2 (n=3458)**

Characteristic	n (%) or Mean (SD)
<i>Demographics</i>	
Age	51.3 (17.0)
Sex – Male	40.2% (1391)
Country – USA	84.2% (2912) ¹
<i>Supplementation</i>	
None	47.9% (1657)
Any	52.1% (1800)
Fish (EPA/DHA) oil	43.6% (1508)
Flaxseed (ALA) oil	1.3% (45)
Krill (EPA/DHA) oil	3.2% (111)
Algal (EPA/DHA) oil	1.8% (62)
Unknown	2.1% (74)
<i>Reported fish intake</i>	
None	31.5% (1090)
Every other week	30.9% (1067)
Weekly	20.6% (714)
Twice per week	10.2% (353)
Three or more times per week	6.8% (234)
<i>O3I value</i>	
Less than 8%	82.6% (2855)
8-12%	15.6% (540)
Above 12%	1.8% (63)

- 497 1. Non-US individuals (n=546), were from 27 other countries
 498 (Singapore (110), India (87), Chile (58), New Zealand (36),
 499 Canada (33), Australia (33), Korea (24), Japan (21), United
 500 Kingdom (19), Norway (19), Philipines (17), Hong Kong (14),
 501 South Africa (13), China (8), Taiwan (5), Sweden (4),
 502 Denmark (4), United Arab Emirates (3), Switzerland (2),
 503 Pakistan (2), Iceland (2), Uruguay (1), Saudia Arabia (1),
 504 Netherlands (1), Mexico (1), Brazil (1) and Brunei (1).
 505 Twenty-six individuals had an unknown country of origin.

506

507 **Table 4. Association between demographic, dietary and supplementation status and O3I**
 508 **values in study 2**

Characteristic	Absolute percentage point increase in O3I per unit of change ¹	
	Bivariate Beta (95% CI)	Multivariable ² Beta (95% CI)
Reported fish meals/week		
Never	--	--
Bi-weekly	0.49% (0.31%, 0.68%) [†]	0.29% [†] (0.12%, 0.45%)
Weekly	1.08% (0.87%, 1.28%) [†]	0.65% [†] (0.46%, 0.83%)
Twice weekly	1.68% (1.42%, 1.94%) [†]	1.18% [†] (0.95%, 1.41%)
Three or more per week	2.57% (2.27%, 2.88%) [†]	1.90%* (1.63%, 2.18%)
EPA/DHA Supplement - Yes	2.36% (2.23%, 2.50%) [†]	2.16% [†] (2.03%, 2.29%)
Sex - Male	-0.09% (-0.25%, 0.06%)	-0.10% (-0.23%, 0.04%)
Age (years/10)	0.22% [†] (0.18%, 0.27%)	0.09% [†] (0.05%, 0.13%)
Country – Not USA ³	0.30%* (0.09%, 0.51%)	0.45% [†] (0.27%, 0.63%)

509 [†]P<0.0001, *P<0.01

510 ¹Values in this table are beta coefficients and are interpreted as the percentage point change in
 511 O3I for a one-unit change in the characteristic, e.g. for each additional fish meal per week the
 512 estimated effect on O3I is 0.6% (or a 0.6 percentage point increase) both before and after
 513 adjusting for other characteristics.

514 ²Overall model R² is 0.33.

515 Equation: O3I = 4.02%+0.29*Biweekly+0.65*Weekly+1.18*Twice+

516 1.90*Three+2.16*Supplement-0.10*Male+0.09*(Age/10)+0.45*Not USA

517

518 ³We also considered a multivariable model which considered groups of non-US countries instead

519 of a US vs. non-US variable. In this more complex model each region was compared to the US,

520 with betas (95% CIs) as follows: Asia 0.49% (0.26, 0.73%)[†], Europe 0.92% (0.40%, 1.45%)[†],

521 South America -0.01% (-0.51%, 0.51%), Africa -0.17% (-1.13%, 0.78%), Australia/NZ 0.32% (-

522 0.15%, 0.79%), Canada 0.95% (0.29%, 1.61%)* and Unknown 0.05% (-0.68%, 0.76%).

523

524 **Table 5. Seventy-five percent¹ prediction intervals based on multivariable model from**
 525 **study 2²**


Fish consumption	Supplement	Not supplement
Never	6.61% (4.43, 8.79)	4.48% (2.30, 6.65)
Bi-weekly	6.91% (4.74, 9.09)	4.78% (2.60, 6.96)
Weekly	7.28% (5.10, 9.46)	5.14% (2.96, 7.32)
Twice weekly	7.84% (5.66, 10.02)	5.71% (3.53, 7.89)
Three or more per week	8.59% (6.41, 10.77)	6.46% (4.28, 8.64)

526

527 ¹Seventy-five percent of people were within the range shown. For example, seventy-five percent
 528 of people eating fish three or more times per week and taking an omega-3 supplement had O3I
 529 values between 6.41 and 10.77%.

530 ²Based on model predicting O3I by supplement, fish consumption and age only. Predictions are
 531 made for someone 50 years old.

532



533

534 **Figure 1.** Omega-3 Index by fish intake and supplementation groups from Study 2 (mean \pm SD).

535